Time-trend Analysis of Clinical Characteristic and Outcomes in Patients With Unprotected Left Main Coronary Artery Disease Treated With PCI Over a 10-year Period
Latest Information Update: 21 Feb 2024
At a glance
- Drugs Pelacarsen (Primary)
- Indications Cardiovascular disorders; Hyperlipoproteinaemia type I
- Focus Therapeutic Use
- 15 Feb 2024 The protocol has been amended to the Interventional Study Model, changing the number of arms from two to one, the masking type to open label, the patient population to 500, the phase to unknown
- 15 Feb 2024 Planned number of patients changed from 17 to 500.
- 15 Feb 2024 Planned End Date changed from 4 Jul 2024 to 7 Feb 2025.